U.S. patent application number 14/992525 was filed with the patent office on 2016-05-05 for 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase.
The applicant listed for this patent is Auspex Pharmaceuticals, Inc.. Invention is credited to Tadimeti Rao, Chengzhi Zhang.
Application Number | 20160122347 14/992525 |
Document ID | / |
Family ID | 43970652 |
Filed Date | 2016-05-05 |
United States Patent
Application |
20160122347 |
Kind Code |
A1 |
Rao; Tadimeti ; et
al. |
May 5, 2016 |
4,6-DIAMINOPYRIMIDINE STIMULATORS OF SOLUBLE GUANYLATE CYCLASE
Abstract
The present invention relates to new 4,6-diaminopyrimidine
stimulators of soluble guanylate cyclase, pharmaceutical
compositions thereof, and methods of use thereof. ##STR00001##
Inventors: |
Rao; Tadimeti; (San Diego,
CA) ; Zhang; Chengzhi; (San Diego, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Auspex Pharmaceuticals, Inc. |
La Jolla |
CA |
US |
|
|
Family ID: |
43970652 |
Appl. No.: |
14/992525 |
Filed: |
January 11, 2016 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12911268 |
Oct 25, 2010 |
9260424 |
|
|
14992525 |
|
|
|
|
61254812 |
Oct 26, 2009 |
|
|
|
Current U.S.
Class: |
514/256 ;
544/328 |
Current CPC
Class: |
A61K 31/506 20130101;
A61P 11/00 20180101; A61P 9/12 20180101; C07B 2200/05 20130101;
A61P 13/12 20180101; A61P 11/06 20180101; C07B 59/002 20130101;
A61K 31/437 20130101; A61K 45/06 20130101; C07D 471/04 20130101;
A61K 2300/00 20130101; A61K 31/506 20130101; A61K 2300/00 20130101;
A61P 25/06 20180101; A61K 31/437 20130101; A61P 9/10 20180101; A61P
3/10 20180101; A61P 19/10 20180101 |
International
Class: |
C07D 471/04 20060101
C07D471/04; A61K 31/506 20060101 A61K031/506; A61K 45/06 20060101
A61K045/06; C07B 59/00 20060101 C07B059/00 |
Claims
1. A compound of structural Formula I ##STR00013## or a salt
thereof, wherein: R.sub.1-R.sub.19 are independently selected from
the group consisting of hydrogen and deuterium; and at least one of
R.sub.1-R.sub.19 is deuterium.
2. The compound as recited in claim 1 wherein at least one of
R.sub.1-R.sub.19 independently has deuterium enrichment of no less
than about 10%.
3. The compound as recited in claim 1 wherein at least one of
R.sub.1-R.sub.19 independently has deuterium enrichment of no less
than about 50%.
4. The compound as recited in claim 1 wherein at least one of
R.sub.1-R.sub.19 independently has deuterium enrichment of no less
than about 90%.
5. The compound as recited in claim 1 wherein at least one of
R.sub.1-R.sub.19 independently has deuterium enrichment of no less
than about 98%.
6. The compound as recited in claim 1 wherein said compound has a
structural formula selected from the group consisting of:
##STR00014## ##STR00015## ##STR00016## ##STR00017## ##STR00018##
##STR00019## ##STR00020##
7. The compound as recited in claim 1 wherein said compound has a
structural formula selected from the group consisting of:
##STR00021##
8. The compound as recited in claim 7 wherein each position
represented as D has deuterium enrichment of no less than about
10%.
9. The compound as recited in claim 7 wherein each position
represented as D has deuterium enrichment of no less than about
50%.
10. The compound as recited in claim 7 wherein each position
represented as D has deuterium enrichment of no less than about
90%.
11. The compound as recited in claim 7 wherein each position
represented as D has deuterium enrichment of no less than about
98%.
12. The compound as recited in claim 7 wherein said compound has
the structural formula: ##STR00022##
13. The compound as recited in claim 7 wherein said compound has
the structural formula: ##STR00023##
14. The compound as recited in claim 7 wherein said compound has
the structural formula: ##STR00024##
15. The compound as recited in claim 7 wherein said compound has
the structural formula: ##STR00025##
16. The compound as recited in claim 7 wherein said compound has
the structural formula: ##STR00026##
17. The compound as recited in claim 7 wherein said compound has
the structural formula: ##STR00027##
18. A pharmaceutical composition comprising a compound as recited
in claim 1 together with a pharmaceutically acceptable carrier.
19. A method of treatment of a soluble guanylate cyclase-mediated
disorder comprising the administration of a therapeutically
effective amount of a compound as recited in claim 1 to a patient
in need thereof.
20. The method as recited in claim 19 wherein said disorder is
selected from the group consisting of chronic thromboembolic
pulmonary hypertension, pulmonary arterial hypertension, asthma,
hypertension, atherosclerosis, osteoporosis, thromboembolism,
genitourinary disorders, bronchoconstriction, chronic obstructive
pulmonary disease, acute respiratory distress syndrome, pulmonary
vasoconstriction, migraine, migraine with vertigo, optic nerve
damage, glaucoma cerebrovascular disorders, cerebrovasospasm,
stroke, transient ischemic attacks, cerebral autosomal dominant
arteriopathy with subcortical infarcts and leukoencephalopathy,
fibrotic disorders, renal disorders, non-alcoholic hepatosteatosis,
hepatitis, diabetic nephropathy, idiopathic pulmonary fibrosis.
21. The method as recited in claim 19 further comprising the
administration of an additional therapeutic agent.
22. The method as recited in claim 21 wherein said additional
therapeutic agent is selected from the group consisting of
antihypertensives and PDE5 inhibitors.
23. The method as recited in claim 22 wherein said antihypertensive
is selected from the group consisting of metoprolol,
hydrochlorothiazide, aliskiren, valsartan, candesartan, amlodipine,
olmesartan, medoxomil, azelnidipine, azilsartan, azilsartan
medoxomil potassium, chlorthalidone, darusentan, fimasartan,
olmesartan medoxomil, pratosartan, telmisartan, ADX-415, AR-9281,
angiotensin vaccine/CoVaccine HT, cholecalciferol, daglutril,
flavangenol, INT-001, LCI-699, LCZ-696, lisinopril, MK-0736,
PL-3994, PS-433540, rostafuroxine, S-(+)-mecamylamine, SLx-2101,
SPP-635, sapropterin, TBC-3711, udenafil, MC-4262, mirodenafil,
NV-04, SPP-1148, SPP-676, TAK-591, VNP-489, rhACE2, allisartan,
BNP-054, CGEN-856, CGEN-857, INT-002, QGC-001, SLV-316, tempol,
urocortin 2, and XL-550.
24. The method as recited in claim 22 wherein said PDE5 inhibitor
is selected from the group consisting of vardenafil, sildenafil,
and tadalafil.
25. The method as recited in claim 19, further resulting in at
least one effect selected from the group consisting of: a.
decreased inter-individual variation in plasma levels of said
compound or a metabolite thereof as compared to the
non-isotopically enriched compound; b. increased average plasma
levels of said compound per dosage unit thereof as compared to the
non-isotopically enriched compound; c. decreased average plasma
levels of at least one metabolite of said compound per dosage unit
thereof as compared to the non-isotopically enriched compound; d.
increased average plasma levels of at least one metabolite of said
compound per dosage unit thereof as compared to the
non-isotopically enriched compound; and e. an improved clinical
effect during the treatment in said subject per dosage unit thereof
as compared to the non-isotopically enriched compound.
26. The method as recited in claim 19, further resulting in at
least two effects selected from the group consisting of: a.
decreased inter-individual variation in plasma levels of said
compound or a metabolite thereof as compared to the
non-isotopically enriched compound; b. increased average plasma
levels of said compound per dosage unit thereof as compared to the
non-isotopically enriched compound; c. decreased average plasma
levels of at least one metabolite of said compound per dosage unit
thereof as compared to the non-isotopically enriched compound; d.
increased average plasma levels of at least one metabolite of said
compound per dosage unit thereof as compared to the
non-isotopically enriched compound; and e. an improved clinical
effect during the treatment in said subject per dosage unit thereof
as compared to the non-isotopically enriched compound.
27. The method as recited in claim 19, wherein the method effects a
decreased metabolism of the compound per dosage unit thereof by at
least one polymorphically-expressed cytochrome P.sub.450 isoform in
the subject, as compared to the corresponding non-isotopically
enriched compound.
28. The method as recited in claim 27, wherein the cytochrome
P.sub.450 isoform is selected from the group consisting of CYP2C8,
CYP2C9, CYP2C19, and CYP2D6.
29. The method as recited claim 19, wherein said compound is
characterized by decreased inhibition of at least one cytochrome
P.sub.450 or monoamine oxidase isoform in said subject per dosage
unit thereof as compared to the non-isotopically enriched
compound.
30. The method as recited in claim 29, wherein said cytochrome
P.sub.450 or monoamine oxidase isoform is selected from the group
consisting of CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2A13, CYP2B6,
CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP2G1, CYP2J2,
CYP2R1, CYP2S1, CYP3A4, CYP3A5, CYP3A5P1, CYP3A5P2, CYP3A7,
CYP4A11, CYP4B1, CYP4F2, CYP4F3, CYP4F8, CYP4F11, CYP4F12, CYP4X1,
CYP4Z1, CYP5A1, CYP7A1, CYP7B1, CYP8A1, CYP8B1, CYP11A1, CYP11B1,
CYP11B2, CYP17, CYP19, CYP21, CYP24, CYP26A1, CYP26B1, CYP27A1,
CYP27B1, CYP39, CYP46, CYP51, MAO.sub.A, and MAO.sub.B.
31. The method as recited in claim 19, wherein the method reduces a
deleterious change in a diagnostic hepatobiliary function endpoint,
as compared to the corresponding non-isotopically enriched
compound.
32. The method as recited in claim 31, wherein the diagnostic
hepatobiliary function endpoint is selected from the group
consisting of alanine aminotransferase ("ALT"), serum
glutamic-pyruvic transaminase ("SGPT"), aspartate aminotransferase
("AST," "SGOT"), ALT/AST ratios, serum aldolase, alkaline
phosphatase ("ALP"), ammonia levels, bilirubin, gamma-glutamyl
transpeptidase ("GGTP," ".gamma.-GTP," "GGT"), leucine
aminopeptidase ("LAP"), liver biopsy, liver ultrasonography, liver
nuclear scan, 5'-nucleotidase, and blood protein.
33. A compound as recited in claim 1 for use as a medicament.
34. A compound as recited in claim 1 for use in the manufacture of
a medicament for the prevention or treatment of a disorder
ameliorated by the stimulation of soluble guanylate cyclase.
Description
[0001] This application is a continuation of U.S. application Ser.
No. 12/911,268, filed Oct. 25, 2010, which claims the benefit of
priority of U.S. Provisional Application No. 61/254,812, filed Oct.
26, 2009, the disclosures of which are hereby incorporated by
reference as if written herein in its entirety.
[0002] Disclosed herein are new 4,6-diaminopyrimidine compounds and
compositions and their application as pharmaceuticals for the
treatment of disorders. Methods of stimulation of soluble guanylate
cyclase activity in a subject are also provided for the treatment
of disorders such as chronic thromboembolic pulmonary hypertension,
pulmonary arterial hypertension, asthma, hypertension,
atherosclerosis, osteoporosis, thromboembolism, genitourinary
disorders, bronchoconstriction, chronic obstructive pulmonary
disease, acute respiratory distress syndrome, pulmonary
vasoconstriction, migraine, migraine with vertigo, optic nerve
damage, glaucoma cerebrovascular disorders, cerebrovasospasm,
stroke, transient ischemic attacks, cerebral autosomal dominant
arteriopathy with subcortical infarcts and leukoencephalopathy,
fibrotic disorders, renal disorders, non-alcoholic hepatosteatosis,
hepatitis, diabetic nephropathy, idiopathic pulmonary fibrosis.
[0003] Riociguat (BAY 63-2521),
N-[4,6-Diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrim-
idin-5-yl]-N-methylcarbamic acid methyl ester, is a soluble
guanylate cyclase stimulator. Riociguat is under investigation for
the treatment of chronic thromboembolic pulmonary hypertension, and
pulmonary arterial hypertension. Michelakis et al., Eur. Respir.
J., 2009, 33(4), 717-21; Ghofrani et al., Eur. Respir. Rev., 2009,
18(111), 35-41; Mittendorf et al., ChemMedChem, 2009, 4, 853-65;
and WO 2006037491. Riociguat has also shown promise in treating
hypertension, angina pectoris, heart failure, atherosclerosis,
thromboembolism, platelet activation, asthma, bronchoconstriction,
chronic obstructive pulmonary disease, pulmonary vasoconstriction,
acute respiratory distress syndrome, cerebral autosomal dominant
arteriopathy with subcortical infarcts and leukoencephalopathy,
cerebrovascular disorders, cerebrovasospasm, transient ischemic
attacks, stroke, migraine, migraine with vertigo, genitourinary
disorders, benign prostate syndrome, benign prostate hyperplasia,
benign prostate enlargement, urinary incontinence, bladder outlet
obstruction, neurogenic bladder syndrome, pelvic pain, prostate
hypertrophy, sexual dysfunction, Raynaud's phenomenon, increased
cellular proliferation, endothelial dysfunction, erectile
dysfunction wounds, scarring, fibrotic disorders, renal disorders,
renal failure, renal hypertension, idiopathic pulmonary fibrosis,
non-alcoholic hepatosteatosis, hepatitis, diabetic nephropathy,
hypercholesterolemia, osteoporosis, optic nerve damage, and
glaucoma. Gur et al., Curr. Pharm. Design., 2010, 16, 1619-33; WO
2010081647; WO 2008138483; WO 2007009607; US 20070225299; US
20090215769; US 20090221573; and U.S. Pat. No. 7,173,037.
##STR00002##
[0004] Adverse effects associated with riociguat include headache,
nasal congestion, flushing, overheating sensation, orthostatic
hypotension, and heart palpitations.
Deuterium Kinetic Isotope Effect
[0005] In order to eliminate foreign substances such as therapeutic
agents, the animal body expresses various enzymes, such as the
cytochrome P.sub.450 enzymes (CYPs), esterases, proteases,
reductases, dehydrogenases, and monoamine oxidases, to react with
and convert these foreign substances to more polar intermediates or
metabolites for renal excretion. Such metabolic reactions
frequently involve the oxidation of a carbon-hydrogen (C--H) bond
to either a carbon-oxygen (C--O) or a carbon-carbon (C--C)
.pi.-bond. The resultant metabolites may be stable or unstable
under physiological conditions, and can have substantially
different pharmacokinetic, pharmacodynamic, and acute and long-term
toxicity profiles relative to the parent compounds. For most drugs,
such oxidations are generally rapid and ultimately lead to
administration of multiple or high daily doses.
[0006] The relationship between the activation energy and the rate
of reaction may be quantified by the Arrhenius equation,
k=Ae.sup.-Eact/RT. The Arrhenius equation states that, at a given
temperature, the rate of a chemical reaction depends exponentially
on the activation energy (E.sub.act).
[0007] The transition state in a reaction is a short lived state
along the reaction pathway during which the original bonds have
stretched to their limit. By definition, the activation energy
E.sub.act for a reaction is the energy required to reach the
transition state of that reaction. Once the transition state is
reached, the molecules can either revert to the original reactants,
or form new bonds giving rise to reaction products. A catalyst
facilitates a reaction process by lowering the activation energy
leading to a transition state. Enzymes are examples of biological
catalysts.
[0008] Carbon-hydrogen bond strength is directly proportional to
the absolute value of the ground-state vibrational energy of the
bond. This vibrational energy depends on the mass of the atoms that
form the bond, and increases as the mass of one or both of the
atoms making the bond increases. Since deuterium (D) has twice the
mass of protium (.sup.1H), a C-D bond is stronger than the
corresponding C-.sup.1H bond. If a C-.sup.1H bond is broken during
a rate-determining step in a chemical reaction (i.e. the step with
the highest transition state energy), then substituting a deuterium
for that protium will cause a decrease in the reaction rate. This
phenomenon is known as the Deuterium Kinetic Isotope Effect (DKIE).
The magnitude of the DKIE can be expressed as the ratio between the
rates of a given reaction in which a C-.sup.1H bond is broken, and
the same reaction where deuterium is substituted for protium. The
DKIE can range from about 1 (no isotope effect) to very large
numbers, such as 50 or more. Substitution of tritium for hydrogen
results in yet a stronger bond than deuterium and gives numerically
larger isotope effects.
[0009] Deuterium (.sup.2H or D) is a stable and non-radioactive
isotope of hydrogen which has approximately twice the mass of
protium (.sup.1H), the most common isotope of hydrogen. Deuterium
oxide (D.sub.2O or "heavy water") looks and tastes like H.sub.2O,
but has different physical properties.
[0010] When pure D.sub.2O is given to rodents, it is readily
absorbed. The quantity of deuterium required to induce toxicity is
extremely high. When about 0-15% of the body water has been
replaced by D.sub.2O, animals are healthy but are unable to gain
weight as fast as the control (untreated) group. When about 15-20%
of the body water has been replaced with D.sub.2O, the animals
become excitable. When about 20-25% of the body water has been
replaced with D.sub.2O, the animals become so excitable that they
go into frequent convulsions when stimulated. Skin lesions, ulcers
on the paws and muzzles, and necrosis of the tails appear. The
animals also become very aggressive. When about 30% of the body
water has been replaced with D.sub.2O, the animals refuse to eat
and become comatose. Their body weight drops sharply and their
metabolic rates drop far below normal, with death occurring at
about 30 to about 35% replacement with D.sub.2O. The effects are
reversible unless more than thirty percent of the previous body
weight has been lost due to D.sub.2O. Studies have also shown that
the use of D.sub.2O can delay the growth of cancer cells and
enhance the cytotoxicity of certain antineoplastic agents.
[0011] Deuteration of pharmaceuticals to improve pharmacokinetics
(PK), pharmacodynamics (PD), and toxicity profiles has been
demonstrated previously with some classes of drugs. For example,
the DKIE was used to decrease the hepatotoxicity of halothane,
presumably by limiting the production of reactive species such as
trifluoroacetyl chloride. However, this method may not be
applicable to all drug classes. For example, deuterium
incorporation can lead to metabolic switching. Metabolic switching
occurs when xenogens, sequestered by Phase I enzymes, bind
transiently and re-bind in a variety of conformations prior to the
chemical reaction (e.g., oxidation). Metabolic switching is enabled
by the relatively vast size of binding pockets in many Phase I
enzymes and the promiscuous nature of many metabolic reactions.
Metabolic switching can lead to different proportions of known
metabolites as well as altogether new metabolites. This new
metabolic profile may impart more or less toxicity. Such pitfalls
are non-obvious and are not predictable a priori for any drug
class.
[0012] Riociguat is a soluble guanylate cyclase stimulator. The
carbon-hydrogen bonds of riociguat contain a naturally occurring
distribution of hydrogen isotopes, namely .sup.1H or protium (about
99.9844%), .sup.2H or deuterium (about 0.0156%), and .sup.3H or
tritium (in the range between about 0.5 and 67 tritium atoms per
10.sup.18 protium atoms). Increased levels of deuterium
incorporation may produce a detectable Deuterium Kinetic Isotope
Effect (DKIE) that could effect the pharmacokinetic, pharmacologic
and/or toxicologic profiles of such riociguat in comparison with
the compound having naturally occurring levels of deuterium.
[0013] Based on discoveries made in our laboratory, as well as
considering the literature, riociguat is likely metabolized in
humans at the N-methyl group and the benzylic methylene group. The
current approach has the potential to prevent metabolism at these
sites. Other sites on the molecule may also undergo transformations
leading to metabolites with as-yet-unknown pharmacology/toxicology.
Limiting the production of these metabolites has the potential to
decrease the danger of the administration of such drugs and may
even allow increased dosage and/or increased efficacy. All of these
transformations can occur through polymorphically-expressed
enzymes, exacerbating interpatient variability. Further, some
disorders are best treated when the subject is medicated around the
clock or for an extended period of time. For all of the foregoing
reasons, a medicine with a longer half-life may result in greater
efficacy and cost savings. Various deuteration patterns can be used
to (a) reduce or eliminate unwanted metabolites, (b) increase the
half-life of the parent drug, (c) decrease the number of doses
needed to achieve a desired effect, (d) decrease the amount of a
dose needed to achieve a desired effect, (e) increase the formation
of active metabolites, if any are formed, (f) decrease the
production of deleterious metabolites in specific tissues, and/or
(g) create a more effective drug and/or a safer drug for
polypharmacy, whether the polypharmacy be intentional or not. The
deuteration approach has the strong potential to slow the
metabolism of riociguat and attenuate interpatient variability.
[0014] Novel compounds and pharmaceutical compositions, certain of
which have been found to stimulate soluble guanylate cyclase have
been discovered, together with methods of synthesizing and using
the compounds, including methods for the treatment of soluble
guanylate cyclase-mediated disorders in a patient by administering
the compounds.
[0015] In certain embodiments of the present invention, compounds
have structural Formula I:
##STR00003##
or a salt thereof, wherein:
[0016] R.sub.1-R.sub.19 are independently selected from the group
consisting of hydrogen and deuterium; and
[0017] at least one of R.sub.1-R.sub.19 is deuterium.
[0018] Certain compounds disclosed herein may possess useful
soluble guanylate cyclase stimulating activity, and may be used in
the treatment or prophylaxis of a disorder in which soluble
guanylate cyclase plays an active role. Thus, certain embodiments
also provide pharmaceutical compositions comprising one or more
compounds disclosed herein together with a pharmaceutically
acceptable carrier, as well as methods of making and using the
compounds and compositions. Certain embodiments provide methods for
stimulating soluble guanylate cyclase. Other embodiments provide
methods for treating a soluble guanylate cyclase-mediated disorder
in a patient in need of such treatment, comprising administering to
said patient a therapeutically effective amount of a compound or
composition according to the present invention. Also provided is
the use of certain compounds disclosed herein for use in the
manufacture of a medicament for the prevention or treatment of a
disorder ameliorated by the stimulation of soluble guanylate
cyclase.
[0019] The compounds as disclosed herein may also contain less
prevalent isotopes for other elements, including, but not limited
to, .sup.13C or .sup.14C for carbon, .sup.33S, .sup.34S, or
.sup.36S for sulfur, .sup.15N for nitrogen, and .sup.17O or
.sup.18O for oxygen.
[0020] In certain embodiments, the compound disclosed herein may
expose a patient to a maximum of about 0.000005% D.sub.2O or about
0.00001% DHO, assuming that all of the C-D bonds in the compound as
disclosed herein are metabolized and released as D.sub.2O or DHO.
In certain embodiments, the levels of D.sub.2O shown to cause
toxicity in animals is much greater than even the maximum limit of
exposure caused by administration of the deuterium enriched
compound as disclosed herein. Thus, in certain embodiments, the
deuterium-enriched compound disclosed herein should not cause any
additional toxicity due to the formation of D.sub.2O or DHO upon
drug metabolism.
[0021] In certain embodiments, the deuterated compounds disclosed
herein maintain the beneficial aspects of the corresponding
non-isotopically enriched molecules while substantially increasing
the maximum tolerated dose, decreasing toxicity, increasing the
half-life (T.sub.1/2), lowering the maximum plasma concentration
(C.sub.max) of the minimum efficacious dose (MED), lowering the
efficacious dose and thus decreasing the non-mechanism-related
toxicity, and/or lowering the probability of drug-drug
interactions.
[0022] All publications and references cited herein are expressly
incorporated herein by reference in their entirety. However, with
respect to any similar or identical terms found in both the
incorporated publications or references and those explicitly put
forth or defined in this document, then those terms definitions or
meanings explicitly put forth in this document shall control in all
respects.
[0023] As used herein, the terms below have the meanings
indicated.
[0024] The singular forms "a," "an," and "the" may refer to plural
articles unless specifically stated otherwise.
[0025] The term "about," as used herein, is intended to qualify the
numerical values which it modifies, denoting such a value as
variable within a margin of error. When no particular margin of
error, such as a standard deviation to a mean value given in a
chart or table of data, is recited, the term "about" should be
understood to mean that range which would encompass the recited
value and the range which would be included by rounding up or down
to that figure as well, taking into account significant
figures.
[0026] When ranges of values are disclosed, and the notation "from
n.sub.1 . . . to n.sub.2" or "n.sub.1-n.sub.2" is used, where
n.sub.1 and n.sub.2 are the numbers, then unless otherwise
specified, this notation is intended to include the numbers
themselves and the range between them. This range may be integral
or continuous between and including the end values.
[0027] The term "deuterium enrichment" refers to the percentage of
incorporation of deuterium at a given position in a molecule in the
place of hydrogen. For example, deuterium enrichment of 1% at a
given position means that 1% of molecules in a given sample contain
deuterium at the specified position. Because the naturally
occurring distribution of deuterium is about 0.0156%, deuterium
enrichment at any position in a compound synthesized using
non-enriched starting materials is about 0.0156%. The deuterium
enrichment can be determined using conventional analytical methods
known to one of ordinary skill in the art, including mass
spectrometry and nuclear magnetic resonance spectroscopy.
[0028] The term "is/are deuterium," when used to describe a given
position in a molecule such as R.sub.1-R.sub.19 or the symbol "D",
when used to represent a given position in a drawing of a molecular
structure, means that the specified position is enriched with
deuterium above the naturally occurring distribution of deuterium.
In one embodiment deuterium enrichment is no less than about 1%, in
another no less than about 5%, in another no less than about 10%,
in another no less than about 20%, in another no less than about
50%, in another no less than about 70%, in another no less than
about 80%, in another no less than about 90%, or in another no less
than about 98% of deuterium at the specified position.
[0029] The term "isotopic enrichment" refers to the percentage of
incorporation of a less prevalent isotope of an element at a given
position in a molecule in the place of the more prevalent isotope
of the element.
[0030] The term "non-isotopically enriched" refers to a molecule in
which the percentages of the various isotopes are substantially the
same as the naturally occurring percentages.
[0031] Asymmetric centers exist in the compounds disclosed herein.
These centers are designated by the symbols "R" or "S," depending
on the configuration of substituents around the chiral carbon atom.
It should be understood that the invention encompasses all
stereochemical isomeric forms, including diastereomeric,
enantiomeric, and epimeric forms, as well as d-isomers and
1-isomers, and mixtures thereof. Individual stereoisomers of
compounds can be prepared synthetically from commercially available
starting materials which contain chiral centers or by preparation
of mixtures of enantiomeric products followed by separation such as
conversion to a mixture of diastereomers followed by separation or
recrystallization, chromatographic techniques, direct separation of
enantiomers on chiral chromatographic columns, or any other
appropriate method known in the art. Starting compounds of
particular stereochemistry are either commercially available or can
be made and resolved by techniques known in the art. Additionally,
the compounds disclosed herein may exist as geometric isomers. The
present invention includes all cis, trans, syn, anti, entgegen (E),
and zusammen (Z) isomers as well as the appropriate mixtures
thereof. Additionally, compounds may exist as tautomers; all
tautomeric isomers are provided by this invention. Additionally,
the compounds disclosed herein can exist in unsolvated as well as
solvated forms with pharmaceutically acceptable solvents such as
water, ethanol, and the like. In general, the solvated forms are
considered equivalent to the unsolvated forms.
[0032] The term "bond" refers to a covalent linkage between two
atoms, or two moieties when the atoms joined by the bond are
considered to be part of larger substructure. A bond may be single,
double, or triple unless otherwise specified. A dashed line between
two atoms in a drawing of a molecule indicates that an additional
bond may be present or absent at that position.
[0033] The term "disorder" as used herein is intended to be
generally synonymous, and is used interchangeably with, the terms
"disease" and "condition" (as in medical condition), in that all
reflect an abnormal condition of the human or animal body or of one
of its parts that impairs normal functioning, is typically
manifested by distinguishing signs and symptoms.
[0034] The terms "treat," "treating," and "treatment" are meant to
include alleviating or abrogating a disorder or one or more of the
symptoms associated with a disorder; or alleviating or eradicating
the cause(s) of the disorder itself. As used herein, reference to
"treatment" of a disorder is intended to include prevention. The
terms "prevent," "preventing," and "prevention" refer to a method
of delaying or precluding the onset of a disorder; and/or its
attendant symptoms, barring a subject from acquiring a disorder or
reducing a subject's risk of acquiring a disorder.
[0035] The term "therapeutically effective amount" refers to the
amount of a compound that, when administered, is sufficient to
prevent development of, or alleviate to some extent, one or more of
the symptoms of the disorder being treated. The term
"therapeutically effective amount" also refers to the amount of a
compound that is sufficient to elicit the biological or medical
response of a cell, tissue, system, animal, or human that is being
sought by a researcher, veterinarian, medical doctor, or
clinician.
[0036] The term "subject" refers to an animal, including, but not
limited to, a primate (e.g., human, monkey, chimpanzee, gorilla,
and the like), rodents (e.g., rats, mice, gerbils, hamsters,
ferrets, and the like), lagomorphs, swine (e.g., pig, miniature
pig), equine, canine, feline, and the like. The terms "subject" and
"patient" are used interchangeably herein in reference, for
example, to a mammalian subject, such as a human patient.
[0037] The term "combination therapy" means the administration of
two or more therapeutic agents to treat a therapeutic disorder
described in the present disclosure. Such administration
encompasses co-administration of these therapeutic agents in a
substantially simultaneous manner, such as in a single capsule
having a fixed ratio of active ingredients or in multiple, separate
capsules for each active ingredient. In addition, such
administration also encompasses use of each type of therapeutic
agent in a sequential manner. In either case, the treatment regimen
will provide beneficial effects of the drug combination in treating
the disorders described herein.
[0038] The term "soluble guanylate cyclase" (sGC) refers to a key
signal-transduction enzyme activated by nitric oxide (NO). Nitric
oxide catalyzes the conversion of guanosine-5'-triphosphate (GTP)
into the second messenger cyclic guanosine-3',5'-monophosphate
(cGMP). The increased level of cGMP modulates the activity of
downstream effectors including protein kinases, phosphodiesterases,
and ion channels, ultimately regulating a multitude of fundamental
cellular processes including vasodilatation, vascular smooth-muscle
cell growth, platelet aggregation, and neurotransmission.
Impairments of the NO-sGC-cGMP signaling pathway have been
implicated in the pathogenesis of cardiovascular, pulmonary,
endothelial, renal, and hepatic diseases. Among these, pulmonary
hypertension is a devastating disease in which increased pulmonary
vascular resistance causes right heart hypertrophy, eventually
leading to right heart failure and death. Direct stimulation of
soluble guanylate cyclase represents a promising therapeutic
strategy, particularly for the treatment of pulmonary
hypertension.
[0039] The term "soluble guanylate cyclase-mediated disorder,"
refers to a disorder that is characterized by abnormal soluble
guanylate cyclase activity. A soluble guanylate cyclase-mediated
disorder may be completely or partially mediated by modulating
soluble guanylate cyclase. In particular, a soluble guanylate
cyclase-mediated disorder is one in which stimulation of soluble
guanylate cyclase results in some effect on the underlying disorder
e.g., administration of a soluble guanylate cyclase stimulator
results in some improvement in at least some of the patients being
treated.
[0040] The term "soluble guanylate cyclase stimulator," refers to
the ability of a compound disclosed herein to increase or induce
the activity of soluble guanylate cyclase. Such stimulation may be
manifest only in particular cell types or may be contingent on a
particular biological event. The term "stimulate" or "stimulation"
also refers to altering the function of soluble guanylate cyclase
by increasing the expression of guanylate cyclase, or by increasing
the probability that a complex forms between soluble guanylate
cyclase and a natural substrate. In some embodiments, stimulation
of soluble guanylate cyclase may be assessed using the methods
described in WO 2007009607; U.S. Pat. No. 7,173,037 WO 2010081647;
and Sharkovska et al., J. Hypertension, 2010, 28, 1666-1675.
[0041] The term "therapeutically acceptable" refers to those
compounds (or salts, prodrugs, tautomers, zwitterionic forms, etc.)
which are suitable for use in contact with the tissues of patients
without excessive toxicity, irritation, allergic response,
immunogenecity, are commensurate with a reasonable benefit/risk
ratio, and are effective for their intended use.
[0042] The term "pharmaceutically acceptable carrier,"
"pharmaceutically acceptable excipient," "physiologically
acceptable carrier," or "physiologically acceptable excipient"
refers to a pharmaceutically-acceptable material, composition, or
vehicle, such as a liquid or solid filler, diluent, excipient,
solvent, or encapsulating material. Each component must be
"pharmaceutically acceptable" in the sense of being compatible with
the other ingredients of a pharmaceutical formulation. It must also
be suitable for use in contact with the tissue or organ of humans
and animals without excessive toxicity, irritation, allergic
response, immunogenecity, or other problems or complications,
commensurate with a reasonable benefit/risk ratio. See, Remington:
The Science and Practice of Pharmacy, 21st Edition; Lippincott
Williams & Wilkins: Philadelphia, Pa., 2005; Handbook of
Pharmaceutical Excipients, 5th Edition; Rowe et al., Eds., The
Pharmaceutical Press and the American Pharmaceutical Association:
2005; and Handbook of Pharmaceutical Additives, 3rd Edition; Ash
and Ash Eds., Gower Publishing Company: 2007; Pharmaceutical
Preformulation and Formulation, Gibson Ed., CRC Press LLC: Boca
Raton, Fla., 2004).
[0043] The terms "active ingredient," "active compound," and
"active substance" refer to a compound, which is administered,
alone or in combination with one or more pharmaceutically
acceptable excipients or carriers, to a subject for treating,
preventing, or ameliorating one or more symptoms of a disorder.
[0044] The terms "drug," "therapeutic agent," and "chemotherapeutic
agent" refer to a compound, or a pharmaceutical composition
thereof, which is administered to a subject for treating,
preventing, or ameliorating one or more symptoms of a disorder.
[0045] The term "release controlling excipient" refers to an
excipient whose primary function is to modify the duration or place
of release of the active substance from a dosage form as compared
with a conventional immediate release dosage form.
[0046] The term "nonrelease controlling excipient" refers to an
excipient whose primary function do not include modifying the
duration or place of release of the active substance from a dosage
form as compared with a conventional immediate release dosage
form.
[0047] The term "prodrug" refers to a compound functional
derivative of the compound as disclosed herein and is readily
convertible into the parent compound in vivo. Prodrugs are often
useful because, in some situations, they may be easier to
administer than the parent compound. They may, for instance, be
bioavailable by oral administration whereas the parent compound is
not. The prodrug may also have enhanced solubility in
pharmaceutical compositions over the parent compound. A prodrug may
be converted into the parent drug by various mechanisms, including
enzymatic processes and metabolic hydrolysis. See Harper, Progress
in Drug Research 1962, 4, 221-294; Morozowich et al. in "Design of
Biopharmaceutical Properties through Prodrugs and Analogs," Roche
Ed., APHA Acad. Pharm. Sci. 1977; "Bioreversible Carriers in Drug
in Drug Design, Theory and Application," Roche Ed., APHA Acad.
Pharm. Sci. 1987; "Design of Prodrugs," Bundgaard, Elsevier, 1985;
Wang et al., Curr. Pharm. Design 1999, 5, 265-287; Pauletti et al.,
Adv. Drug. Delivery Rev. 1997, 27, 235-256; Mizen et al., Pharm.
Biotech. 1998, 11, 345-365; Gaignault et al., Pract. Med. Chem.
1996, 671-696; Asgharnejad in "Transport Processes in
Pharmaceutical Systems," Amidon et al., Ed., Marcell Dekker,
185-218, 2000; Balant et al., Eur. J. Drug Metab. Pharmacokinet.
1990, 15, 143-53; Balimane and Sinko, Adv. Drug Delivery Rev. 1999,
39, 183-209; Browne, Clin. Neuropharmacol. 1997, 20, 1-12;
Bundgaard, Arch. Pharm. Chem. 1979, 86, 1-39; Bundgaard, Controlled
Drug Delivery 1987, 17, 179-96; Bundgaard, Adv. Drug Delivery Rev.
1992, 8, 1-38; Fleisher et al., Adv. Drug Delivery Rev. 1996, 19,
115-130; Fleisher et al., Methods Enzymol. 1985, 112, 360-381;
Farquhar et al., J. Pharm. Sci. 1983, 72, 324-325; Freeman et al.,
J. Chem. Soc., Chem. Commun. 1991, 875-877; Friis and Bundgaard,
Eur. J. Pharm. Sci. 1996, 4, 49-59; Gangwar et al., Des. Biopharm.
Prop. Prodrugs Analogs, 1977, 409-421; Nathwani and Wood, Drugs
1993, 45, 866-94; Sinhababu and Thakker, Adv. Drug Delivery Rev.
1996, 19, 241-273; Stella et al., Drugs 1985, 29, 455-73; Tan et
al., Adv. Drug Delivery Rev. 1999, 39, 117-151; Taylor, Adv. Drug
Delivery Rev. 1996, 19, 131-148; Valentino and Borchardt, Drug
Discovery Today 1997, 2, 148-155; Wiebe and Knaus, Adv. Drug
Delivery Rev. 1999, 39, 63-80; Waller et al., Br. J. Clin. Pharmac.
1989, 28, 497-507.
[0048] The compounds disclosed herein can exist as therapeutically
acceptable salts. The term "therapeutically acceptable salt," as
used herein, represents salts or zwitterionic forms of the
compounds disclosed herein which are therapeutically acceptable as
defined herein. The salts can be prepared during the final
isolation and purification of the compounds or separately by
reacting the appropriate compound with a suitable acid or base.
Therapeutically acceptable salts include acid and basic addition
salts. For a more complete discussion of the preparation and
selection of salts, refer to "Handbook of Pharmaceutical Salts,
Properties, and Use," Stah and Wermuth, Ed.; (Wiley-VCH and VHCA,
Zurich, 2002) and Berge et al., J. Pharm. Sci. 1977, 66, 1-19.
[0049] Suitable acids for use in the preparation of
pharmaceutically acceptable salts include, but are not limited to,
acetic acid, 2,2-dichloroacetic acid, acylated amino acids, adipic
acid, alginic acid, ascorbic acid, L-aspartic acid, benzenesulfonic
acid, benzoic acid, 4-acetamidobenzoic acid, boric acid,
(+)-camphoric acid, camphorsulfonic acid,
(+)-(1S)-camphor-10-sulfonic acid, capric acid, caproic acid,
caprylic acid, cinnamic acid, citric acid, cyclamic acid,
cyclohexanesulfamic acid, dodecylsulfuric acid,
ethane-1,2-disulfonic acid, ethanesulfonic acid,
2-hydroxy-ethanesulfonic acid, formic acid, fumaric acid,
galactaric acid, gentisic acid, glucoheptonic acid, D-gluconic
acid, D-glucuronic acid, L-glutamic acid, .alpha.-oxo-glutaric
acid, glycolic acid, hippuric acid, hydrobromic acid, hydrochloric
acid, hydroiodic acid, (+)-L-lactic acid, (.+-.)-DL-lactic acid,
lactobionic acid, lauric acid, maleic acid, (-)-L-malic acid,
malonic acid, (.+-.)-DL-mandelic acid, methanesulfonic acid,
naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid,
1-hydroxy-2-naphthoic acid, nicotinic acid, nitric acid, oleic
acid, orotic acid, oxalic acid, palmitic acid, pamoic acid,
perchloric acid, phosphoric acid, L-pyroglutamic acid, saccharic
acid, salicylic acid, 4-amino-salicylic acid, sebacic acid, stearic
acid, succinic acid, sulfuric acid, tannic acid, (+)-L-tartaric
acid, thiocyanic acid, p-toluenesulfonic acid, undecylenic acid,
and valeric acid.
[0050] Suitable bases for use in the preparation of
pharmaceutically acceptable salts, including, but not limited to,
inorganic bases, such as magnesium hydroxide, calcium hydroxide,
potassium hydroxide, zinc hydroxide, or sodium hydroxide; and
organic bases, such as primary, secondary, tertiary, and
quaternary, aliphatic and aromatic amines, including L-arginine,
benethamine, benzathine, choline, deanol, diethanolamine,
diethylamine, dimethylamine, dipropylamine, diisopropylamine,
2-(diethylamino)-ethanol, ethanolamine, ethylamine,
ethylenediamine, isopropylamine, N-methyl-glucamine, hydrabamine,
1H-imidazole, L-lysine, morpholine, 4-(2-hydroxyethyl)-morpholine,
methylamine, piperidine, piperazine, propylamine, pyrrolidine,
1-(2-hydroxyethyl)-pyrrolidine, pyridine, quinuclidine, quinoline,
isoquinoline, secondary amines, triethanolamine, trimethylamine,
triethylamine, N-methyl-D-glucamine,
2-amino-2-(hydroxymethyl)-1,3-propanediol, and tromethamine.
[0051] While it may be possible for the compounds of the subject
invention to be administered as the raw chemical, it is also
possible to present them as a pharmaceutical composition.
Accordingly, provided herein are pharmaceutical compositions which
comprise one or more of certain compounds disclosed herein, or one
or more pharmaceutically acceptable salts, prodrugs, or solvates
thereof, together with one or more pharmaceutically acceptable
carriers thereof and optionally one or more other therapeutic
ingredients. Proper formulation is dependent upon the route of
administration chosen. Any of the well-known techniques, carriers,
and excipients may be used as suitable and as understood in the
art; e.g., in Remington's Pharmaceutical Sciences. The
pharmaceutical compositions disclosed herein may be manufactured in
any manner known in the art, e.g., by means of conventional mixing,
dissolving, granulating, dragee-making, levigating, emulsifying,
encapsulating, entrapping or compression processes. The
pharmaceutical compositions may also be formulated as a modified
release dosage form, including delayed-, extended-, prolonged-,
sustained-, pulsatile-, controlled-, accelerated- and fast-,
targeted-, programmed-release, and gastric retention dosage forms.
These dosage forms can be prepared according to conventional
methods and techniques known to those skilled in the art (see,
Remington: The Science and Practice of Pharmacy, supra;
Modified-Release Drug Deliver Technology, Rathbone et al., Eds.,
Drugs and the Pharmaceutical Science, Marcel Dekker, Inc.: New
York, N.Y., 2002; Vol. 126).
[0052] The compositions include those suitable for oral, parenteral
(including subcutaneous, intradermal, intramuscular, intravenous,
intraarticular, and intramedullary), intraperitoneal, transmucosal,
transdermal, rectal and topical (including dermal, buccal,
sublingual and intraocular) administration although the most
suitable route may depend upon for example the condition and
disorder of the recipient. The compositions may conveniently be
presented in unit dosage form and may be prepared by any of the
methods well known in the art of pharmacy. Typically, these methods
include the step of bringing into association a compound of the
subject invention or a pharmaceutically salt, prodrug, or solvate
thereof ("active ingredient") with the carrier which constitutes
one or more accessory ingredients. In general, the compositions are
prepared by uniformly and intimately bringing into association the
active ingredient with liquid carriers or finely divided solid
carriers or both and then, if necessary, shaping the product into
the desired formulation.
[0053] Formulations of the compounds disclosed herein suitable for
oral administration may be presented as discrete units such as
capsules, cachets or tablets each containing a predetermined amount
of the active ingredient; as a powder or granules; as a solution or
a suspension in an aqueous liquid or a non-aqueous liquid; or as an
oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The
active ingredient may also be presented as a bolus, electuary or
paste.
[0054] Pharmaceutical preparations which can be used orally include
tablets, push-fit capsules made of gelatin, as well as soft, sealed
capsules made of gelatin and a plasticizer, such as glycerol or
sorbitol. Tablets may be made by compression or molding, optionally
with one or more accessory ingredients. Compressed tablets may be
prepared by compressing in a suitable machine the active ingredient
in a free-flowing form such as a powder or granules, optionally
mixed with binders, inert diluents, or lubricating, surface active
or dispersing agents. Molded tablets may be made by molding in a
suitable machine a mixture of the powdered compound moistened with
an inert liquid diluent. The tablets may optionally be coated or
scored and may be formulated so as to provide slow or controlled
release of the active ingredient therein. All formulations for oral
administration should be in dosages suitable for such
administration. The push-fit capsules can contain the active
ingredients in admixture with filler such as lactose, binders such
as starches, and/or lubricants such as talc or magnesium stearate
and, optionally, stabilizers. In soft capsules, the active
compounds may be dissolved or suspended in suitable liquids, such
as fatty oils, liquid paraffin, or liquid polyethylene glycols. In
addition, stabilizers may be added. Dragee cores are provided with
suitable coatings. For this purpose, concentrated sugar solutions
may be used, which may optionally contain gum arabic, talc,
polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or
titanium dioxide, lacquer solutions, and suitable organic solvents
or solvent mixtures. Dyestuffs or pigments may be added to the
tablets or dragee coatings for identification or to characterize
different combinations of active compound doses.
[0055] The compounds may be formulated for parenteral
administration by injection, e.g., by bolus injection or continuous
infusion. Formulations for injection may be presented in unit
dosage form, e.g., in ampoules or in multi-dose containers, with an
added preservative. The compositions may take such forms as
suspensions, solutions or emulsions in oily or aqueous vehicles,
and may contain formulatory agents such as suspending, stabilizing
and/or dispersing agents. The formulations may be presented in
unit-dose or multi-dose containers, for example sealed ampoules and
vials, and may be stored in powder form or in a freeze-dried
(lyophilized) condition requiring only the addition of the sterile
liquid carrier, for example, saline or sterile pyrogen-free water,
immediately prior to use. Extemporaneous injection solutions and
suspensions may be prepared from sterile powders, granules and
tablets of the kind previously described.
[0056] Formulations for parenteral administration include aqueous
and non-aqueous (oily) sterile injection solutions of the active
compounds which may contain antioxidants, buffers, bacteriostats
and solutes which render the formulation isotonic with the blood of
the intended recipient; and aqueous and non-aqueous sterile
suspensions which may include suspending agents and thickening
agents. Suitable lipophilic solvents or vehicles include fatty oils
such as sesame oil, or synthetic fatty acid esters, such as ethyl
oleate or triglycerides, or liposomes. Aqueous injection
suspensions may contain substances which increase the viscosity of
the suspension, such as sodium carboxymethyl cellulose, sorbitol,
or dextran. Optionally, the suspension may also contain suitable
stabilizers or agents which increase the solubility of the
compounds to allow for the preparation of highly concentrated
solutions.
[0057] In addition to the formulations described previously, the
compounds may also be formulated as a depot preparation. Such long
acting formulations may be administered by implantation (for
example subcutaneously or intramuscularly) or by intramuscular
injection. Thus, for example, the compounds may be formulated with
suitable polymeric or hydrophobic materials (for example as an
emulsion in an acceptable oil) or ion exchange resins, or as
sparingly soluble derivatives, for example, as a sparingly soluble
salt.
[0058] For buccal or sublingual administration, the compositions
may take the form of tablets, lozenges, pastilles, or gels
formulated in conventional manner. Such compositions may comprise
the active ingredient in a flavored basis such as sucrose and
acacia or tragacanth.
[0059] The compounds may also be formulated in rectal compositions
such as suppositories or retention enemas, e.g., containing
conventional suppository bases such as cocoa butter, polyethylene
glycol, or other glycerides.
[0060] Certain compounds disclosed herein may be administered
topically, that is by non-systemic administration. This includes
the application of a compound disclosed herein externally to the
epidermis or the buccal cavity and the instillation of such a
compound into the ear, eye and nose, such that the compound does
not significantly enter the blood stream. In contrast, systemic
administration refers to oral, intravenous, intraperitoneal and
intramuscular administration.
[0061] Formulations suitable for topical administration include
liquid or semi-liquid preparations suitable for penetration through
the skin to the site of inflammation such as gels, liniments,
lotions, creams, ointments or pastes, and drops suitable for
administration to the eye, ear or nose.
[0062] For administration by inhalation, compounds may be delivered
from an insufflator, nebulizer pressurized packs or other
convenient means of delivering an aerosol spray. Pressurized packs
may comprise a suitable propellant such as dichlorodifluoromethane,
trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide
or other suitable gas. In the case of a pressurized aerosol, the
dosage unit may be determined by providing a valve to deliver a
metered amount. Alternatively, for administration by inhalation or
insufflation, the compounds according to the invention may take the
form of a dry powder composition, for example a powder mix of the
compound and a suitable powder base such as lactose or starch. The
powder composition may be presented in unit dosage form, in for
example, capsules, cartridges, gelatin or blister packs from which
the powder may be administered with the aid of an inhalator or
insufflator.
[0063] Preferred unit dosage formulations are those containing an
effective dose, as herein below recited, or an appropriate fraction
thereof, of the active ingredient.
[0064] Compounds may be administered orally or via injection at a
dose of from 0.1 to 500 mg/kg per day. The dose range for adult
humans is generally from 5 mg to 2 g/day. Tablets or other forms of
presentation provided in discrete units may conveniently contain an
amount of one or more compounds which is effective at such dosage
or as a multiple of the same, for instance, units containing 5 mg
to 500 mg, usually around 10 mg to 200 mg.
[0065] The amount of active ingredient that may be combined with
the carrier materials to produce a single dosage form will vary
depending upon the host treated and the particular mode of
administration.
[0066] The compounds can be administered in various modes, e.g.
orally, topically, or by injection. The precise amount of compound
administered to a patient will be the responsibility of the
attendant physician. The specific dose level for any particular
patient will depend upon a variety of factors including the
activity of the specific compound employed, the age, body weight,
general health, sex, diets, time of administration, route of
administration, rate of excretion, drug combination, the precise
disorder being treated, and the severity of the disorder being
treated. Also, the route of administration may vary depending on
the disorder and its severity.
[0067] In the case wherein the patient's condition does not
improve, upon the doctor's discretion the administration of the
compounds may be administered chronically, that is, for an extended
period of time, including throughout the duration of the patient's
life in order to ameliorate or otherwise control or limit the
symptoms of the patient's disorder.
[0068] In the case wherein the patient's status does improve, upon
the doctor's discretion the administration of the compounds may be
given continuously or temporarily suspended for a certain length of
time (i.e., a "drug holiday").
[0069] Once improvement of the patient's conditions has occurred, a
maintenance dose is administered if necessary. Subsequently, the
dosage or the frequency of administration, or both, can be reduced,
as a function of the symptoms, to a level at which the improved
disorder is retained. Patients can, however, require intermittent
treatment on a long-term basis upon any recurrence of symptoms.
[0070] Disclosed herein are methods of treating a soluble guanylate
cyclase-mediated disorder comprising administering to a subject
having or suspected to have such a disorder, a therapeutically
effective amount of a compound as disclosed herein or a
pharmaceutically acceptable salt, solvate, or prodrug thereof.
[0071] Soluble guanylate cyclase-mediated disorders, include, but
are not limited to, chronic thromboembolic pulmonary hypertension,
pulmonary arterial hypertension, myocardial infarction, heart
failure, angina pectoris, hypertension, atherosclerosis, transient
ischemic attacks, thromboembolism, platelet activation, asthma,
bronchoconstriction, chronic obstructive pulmonary disease,
pulmonary vasoconstriction, acute respiratory distress syndrome,
cerebral autosomal dominant arteriopathy with subcortical infarcts
and leukoencephalopathy, cerebrovascular disorders, stroke,
migraine, migraine with vertigo, genitourinary disorders, benign
prostate syndrome, benign prostate hyperplasia, benign prostate
enlargement, urinary incontinence, bladder outlet obstruction,
neurogenic bladder syndrome, pelvic pain, prostate hypertrophy,
sexual dysfunction, erectile dysfunction, Raynaud's phenomenon,
increased cell proliferation, endothelial dysfunction, wounds,
scarring, fibrotic disorders, idiopathic pulmonary fibrosis,
non-alcoholic hepatosteatosis, hepatitis, diabetic nephropathy,
renal disorders, renal hypertension, acute renal failure,
hypercholesterolemia, osteoporosis, glaucoma, optic nerve damage,
and/or any disorder which can lessened, alleviated, or prevented by
administering a soluble guanylate cyclase stimulator.
[0072] In certain embodiments, a method of treating a soluble
guanylate cyclase-mediated disorder comprises administering to the
subject a therapeutically effective amount of a compound of as
disclosed herein, or a pharmaceutically acceptable salt, solvate,
or prodrug thereof, so as to affect: (1) decreased inter-individual
variation in plasma levels of the compound or a metabolite thereof;
(2) increased average plasma levels of the compound or decreased
average plasma levels of at least one metabolite of the compound
per dosage unit; (3) decreased inhibition of, and/or metabolism by
at least one cytochrome P.sub.450 or monoamine oxidase isoform in
the subject; (4) decreased metabolism via at least one
polymorphically-expressed cytochrome P.sub.450 isoform in the
subject; (5) at least one statistically-significantly improved
disorder-control and/or disorder-eradication endpoint; (6) an
improved clinical effect during the treatment of the disorder, (7)
prevention of recurrence, or delay of decline or appearance, of
abnormal alimentary or hepatic parameters as the primary clinical
benefit, or (8) reduction or elimination of deleterious changes in
any diagnostic hepatobiliary function endpoints, as compared to the
corresponding non-isotopically enriched compound.
[0073] In certain embodiments, inter-individual variation in plasma
levels of the compounds as disclosed herein, or metabolites
thereof, is decreased; average plasma levels of the compound as
disclosed herein are increased; average plasma levels of a
metabolite of the compound as disclosed herein are decreased;
inhibition of a cytochrome P.sub.450 or monoamine oxidase isoform
by a compound as disclosed herein is decreased; or metabolism of
the compound as disclosed herein by at least one
polymorphically-expressed cytochrome P.sub.450 isoform is
decreased; by greater than about 5%, greater than about 10%,
greater than about 20%, greater than about 30%, greater than about
40%, or by greater than about 50% as compared to the corresponding
non-isotopically enriched compound.
[0074] Plasma levels of the compound as disclosed herein, or
metabolites thereof, may be measured using the methods described by
Li et al. Rapid Communications in Mass Spectrometry 2005; Frey et
al., J. Clin. Pharmacol., 2008, 48, 926-34.
[0075] Examples of cytochrome P.sub.450 isoforms in a mammalian
subject include, but are not limited to, CYP1A1, CYP1A2, CYP1B1,
CYP2A6, CYP2A13, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6,
CYP2E1, CYP2G1, CYP2J2, CYP2R1, CYP2S1, CYP3A4, CYP3A5, CYP3A5P1,
CYP3A5P2, CYP3A7, CYP4A11, CYP4B1, CYP4F2, CYP4F3, CYP4F8, CYP4F11,
CYP4F12, CYP4X1, CYP4Z1, CYP5A1, CYP7A1, CYP7B1, CYP8A1, CYP8B1,
CYP11A1, CYP11B1, CYP11B2, CYP17, CYP19, CYP21, CYP24, CYP26A1,
CYP26B1, CYP27A1, CYP27B1, CYP39, CYP46, and CYP51.
[0076] Examples of monoamine oxidase isoforms in a mammalian
subject include, but are not limited to, MAO.sub.A, and
MAO.sub.B.
[0077] The inhibition of the cytochrome P.sub.450 isoform is
measured by the method of Ko et al. (British Journal of Clinical
Pharmacology, 2000, 49, 343-351). The inhibition of the MAO.sub.A
isoform is measured by the method of Weyler et al. (J. Biol Chem.
1985, 260, 13199-13207). The inhibition of the MAO.sub.B isoform is
measured by the method of Uebelhack et al. (Pharmacopsychiatry,
1998, 31, 187-192).
[0078] Examples of polymorphically-expressed cytochrome P.sub.450
isoforms in a mammalian subject include, but are not limited to,
CYP2C8, CYP2C9, CYP2C19, and CYP2D6.
[0079] The metabolic activities of liver microsomes, cytochrome
P.sub.450 isoforms, and monoamine oxidase isoforms are measured by
the methods described herein.
[0080] Examples of improved disorder-control and/or
disorder-eradication endpoints, or improved clinical effects
include, but are not limited to, improved cardiopulmonary
haemodynamics, improved Pulmonary Vascular Resistance (PVR), change
from baseline in N-terminal pro b-type natriuretic peptide (NT-pro
BNP), change from baseline in WHO functional class, improved Borg
Dyspnoea score, improved time to clinical worsening, change from
baseline in EQ-5D and LPH, improved six minute walk test, improved
right heart catheter invasive hemodynamics, improved echo imaging,
improved mean pulmonary arterial pressure, improved cardiac index,
reduced systolic blood pressure, reduced blood pressure, reduced
heart rate, and improved electrocardiogram.
[0081] Examples of diagnostic hepatobiliary function endpoints
include, but are not limited to, alanine aminotransferase ("ALT"),
serum glutamic-pyruvic transaminase ("SGPT"), aspartate
aminotransferase ("AST" or "SGOT"), ALT/AST ratios, serum aldolase,
alkaline phosphatase ("ALP"), ammonia levels, bilirubin,
gamma-glutamyl transpeptidase ("GGTP," ".gamma.-GTP," or "GGT"),
leucine aminopeptidase ("LAP"), liver biopsy, liver
ultrasonography, liver nuclear scan, 5'-nucleotidase, and blood
protein. Hepatobiliary endpoints are compared to the stated normal
levels as given in "Diagnostic and Laboratory Test Reference",
4.sup.th edition, Mosby, 1999. These assays are run by accredited
laboratories according to standard protocol.
[0082] Besides being useful for human treatment, certain compounds
and formulations disclosed herein may also be useful for veterinary
treatment of companion animals, exotic animals and farm animals,
including mammals, rodents, and the like. More preferred animals
include horses, dogs, and cats.
Combination Therapy
[0083] The compounds disclosed herein may also be combined or used
in combination with other agents useful in the treatment of soluble
guanylate cyclase-mediated disorders. Or, by way of example only,
the therapeutic effectiveness of one of the compounds described
herein may be enhanced by administration of an adjuvant (i.e., by
itself the adjuvant may only have minimal therapeutic benefit, but
in combination with another therapeutic agent, the overall
therapeutic benefit to the patient is enhanced).
[0084] Such other agents, adjuvants, or drugs, may be administered,
by a route and in an amount commonly used therefor, simultaneously
or sequentially with a compound as disclosed herein. When a
compound as disclosed herein is used contemporaneously with one or
more other drugs, a pharmaceutical composition containing such
other drugs in addition to the compound disclosed herein may be
utilized, but is not required.
[0085] In certain embodiments, the compounds disclosed herein can
be combined with one or more antihypertensives or PDE5
inhibitors.
[0086] In certain embodiments, the compounds disclosed herein can
be combined with one or more antihypertensives, including, but not
limited to, metoprolol, hydrochlorothiazide, aliskiren, valsartan,
candesartan, amlodipine, olmesartan, medoxomil, azelnidipine,
azilsartan, azilsartan medoxomil potassium, chlorthalidone,
darusentan, fimasartan, olmesartan medoxomil, pratosartan,
telmisartan, ADX-415, AR-9281, angiotensin vaccine/CoVaccine HT,
cholecalciferol, daglutril, flavangenol, INT-001, LCI-699, LCZ-696,
lisinopril, MK-0736, PL-3994, PS-433540, rostafuroxine,
S-(+)-mecamylamine, SLx-2101, SPP-635, sapropterin, TBC-3711,
udenafil, MC-4262, mirodenafil, NV-04, SPP-1148, SPP-676, TAK-591,
VNP-489, rhACE2, allisartan, BNP-054, CGEN-856, CGEN-857, INT-002,
QGC-001, SLV-316, tempol, urocortin 2, and XL-550.
[0087] In certain embodiments, the compounds disclosed herein can
be combined with one or more PDE5 inhibitors, including, but not
limited to, vardenafil, sildenafil, and tadalafil.
[0088] The compounds disclosed herein can also be administered in
combination with other classes of compounds, including, but not
limited to, norepinephrine reuptake inhibitors (NRIs) such as
atomoxetine; dopamine reuptake inhibitors (DARIs), such as
methylphenidate; serotonin-norepinephrine reuptake inhibitors
(SNRIs), such as milnacipran; sedatives, such as diazepham;
norepinephrine-dopamine reuptake inhibitor (NDRIs), such as
bupropion; serotonin-norepinephrine-dopamine-reuptake-inhibitors
(SNDRIs), such as venlafaxine; monoamine oxidase inhibitors, such
as selegiline; hypothalamic phospholipids; endothelin converting
enzyme (ECE) inhibitors, such as phosphoramidon; opioids, such as
tramadol; thromboxane receptor antagonists, such as ifetroban;
potassium channel openers; thrombin inhibitors, such as hirudin;
hypothalamic phospholipids; growth factor inhibitors, such as
modulators of PDGF activity; platelet activating factor (PAF)
antagonists; anti-platelet agents, such as GPIIb/IIIa blockers
(e.g., abdximab, eptifibatide, and tirofiban), P2Y(AC) antagonists
(e.g., clopidogrel, ticlopidine and CS-747), and aspirin;
anticoagulants, such as warfarin; low molecular weight heparins,
such as enoxaparin; Factor VIIa Inhibitors and Factor Xa
Inhibitors; renin inhibitors; neutral endopeptidase (NEP)
inhibitors; vasopepsidase inhibitors (dual NEP-ACE inhibitors),
such as omapatrilat and gemopatrilat; HMG CoA reductase inhibitors,
such as pravastatin, lovastatin, atorvastatin, simvastatin, NK-104
(a.k.a. itavastatin, nisvastatin, or nisbastatin), and ZD-4522
(also known as rosuvastatin, or atavastatin or visastatin);
squalene synthetase inhibitors; fibrates; bile acid sequestrants,
such as questran; niacin; anti-atherosclerotic agents, such as ACAT
inhibitors; MTP Inhibitors; calcium channel blockers, such as
amlodipine besylate; potassium channel activators; alpha-muscarinic
agents; beta-muscarinic agents, such as carvedilol and metoprolol;
antiarrhythmic agents; diuretics, such as chlorothiazide,
hydrochiorothiazide, flumethiazide, hydroflumethiazide,
bendroflumethiazide, methylchlorothiazide, trichioromethiazide,
polythiazide, benzothlazide, ethacrynic acid, tricrynafen,
chlorthalidone, furosenilde, musolimine, bumetanide, triamterene,
amiloride, and spironolactone; thrombolytic agents, such as tissue
plasminogen activator (tPA), recombinant tPA, streptokinase,
urokinase, prourokinase, and anisoylated plasminogen streptokinase
activator complex (APSAC); anti-diabetic agents, such as biguanides
(e.g. metformin), glucosidase inhibitors (e.g., acarbose),
insulins, meglitinides (e.g., repaglinide), sulfonylureas (e.g.,
glimepiride, glyburide, and glipizide), thiozolidinediones (e.g.
troglitazone, rosiglitazone and pioglitazone), and PPAR-gamma
agonists; mineralocorticoid receptor antagonists, such as
spironolactone and eplerenone; growth hormone secretagogues; aP2
inhibitors; phosphodiesterase inhibitors, such as PDE III
inhibitors (e.g., cilostazol) and PDE V inhibitors (e.g.,
sildenafil, tadalafil, vardenafil); protein tyrosine kinase
inhibitors; antiinflammatories; antiproliferatives, such as
methotrexate, FK506 (tacrolimus, Prograf), mycophenolate mofetil;
chemotherapeutic agents; immunosuppressants; anticancer agents and
cytotoxic agents (e.g., alkylating agents, such as nitrogen
mustards, alkyl sulfonates, nitrosoureas, ethylenimines, and
triazenes); antimetabolites, such as folate antagonists, purine
analogues, and pyrridine analogues; antibiotics, such as
anthracyclines, bleomycins, mitomycin, dactinomycin, and
plicamycin; enzymes, such as L-asparaginase; farnesyl-protein
transferase inhibitors; hormonal agents, such as glucocorticoids
(e.g., cortisone), estrogens/antiestrogens,
androgens/antiandrogens, progestins, and luteinizing
hormone-releasing hormone anatagonists, and octreotide acetate;
microtubule-disruptor agents, such as ecteinascidins;
microtubule-stablizing agents, such as pacitaxel, docetaxel, and
epothilones A-F; plant-derived products, such as vinca alkaloids,
epipodophyllotoxins, and taxanes; and topoisomerase inhibitors;
prenyl-protein transferase inhibitors; and cyclosporins; steroids,
such as prednisone and dexamethasone; cytotoxic drugs, such as
azathiprine and cyclophosphamide; TNF-alpha inhibitors, such as
tenidap; anti-TNF antibodies or soluble TNF receptor, such as
etanercept, rapamycin, and leflunimide; and cyclooxygenase-2
(COX-2) inhibitors, such as celecoxib and rofecoxib; and
miscellaneous agents such as, hydroxyurea, procarbazine, mitotane,
hexamethylmelamine, gold compounds, platinum coordination
complexes, such as cisplatin, satraplatin, and carboplatin.
[0089] Thus, in another aspect, certain embodiments provide methods
for treating soluble guanylate cyclase-mediated disorders in a
human or animal subject in need of such treatment comprising
administering to said subject an amount of a compound disclosed
herein effective to reduce or prevent said disorder in the subject,
in combination with at least one additional agent for the treatment
of said disorder that is known in the art. In a related aspect,
certain embodiments provide therapeutic compositions comprising at
least one compound disclosed herein in combination with one or more
additional agents for the treatment of soluble guanylate
cyclase-mediated disorders.
General Synthetic Methods for Preparing Compounds
[0090] Isotopic hydrogen can be introduced into a compound as
disclosed herein by synthetic techniques that employ deuterated
reagents, whereby incorporation rates are pre-determined; and/or by
exchange techniques, wherein incorporation rates are determined by
equilibrium conditions, and may be highly variable depending on the
reaction conditions. Synthetic techniques, where tritium or
deuterium is directly and specifically inserted by tritiated or
deuterated reagents of known isotopic content, may yield high
tritium or deuterium abundance, but can be limited by the chemistry
required. Exchange techniques, on the other hand, may yield lower
tritium or deuterium incorporation, often with the isotope being
distributed over many sites on the molecule.
[0091] The compounds as disclosed herein can be prepared by methods
known to one of skill in the art and routine modifications thereof,
and/or following procedures similar to those described in the
Example section herein and routine modifications thereof, and/or
procedures found in US 20070225299; U.S. Pat. No. 7,173,037; and
Mittendorf et al., ChemMedChem, 2009, 4, 853-65, which are hereby
incorporated in their entirety, and references cited therein and
routine modifications thereof. Compounds as disclosed herein can
also be prepared as shown in any of the following schemes and
routine modifications thereof.
[0092] The following scheme can be used to practice the present
invention. Any position shown as hydrogen may optionally be
replaced with deuterium.
##STR00004## ##STR00005##
[0093] Compound 1 is reacted with compound 2 in the presence of an
appropriate base, such as sodium ethoxide, to give compound 3.
Compound 4 is reacted with compound 5 in an appropriate solvent,
such as ethanol, to give compound 6. Compound 3 is reacted with
compound 6 in the presence of an appropriate acid, such as
trifluoroacetic acid, in an appropriate solvent, such as dioxane,
to give compound 7. Compound 7 is reacted with compound 8 in the
presence of an appropriate acid, such as trifluoroacetic acid, in
an appropriate solvent, such as dioxane, to give compound 9.
Compound 9 is treated with an appropriate aminating agent, such as
ammonia, in an appropriate solvent, such as methanol, to give
compound 10. Compound 10 is treated with an appropriate dehydrating
agent, such as trifluoroacetic anhydride, in the presence of an
appropriate base, such as pyridine, in an appropriate solvent, such
as tetrahydrofuran, to give compound 11. Compound 11 is treated
with an appropriate base, such as sodium methoxide, in an
appropriate solvent, such as methanol, to give compound 12.
Compound 12 is reacted with an appropriate aminating agent, such as
ammonium chloride, in the presence of an appropriate acid, such as
acetic acid, in an appropriate solvent, such as methanol, to give
compound 13. Compound 13 is reacted with compound 14 in the
presence of an appropriate base, such as sodium methoxide, in an
appropriate solvent, such as dimethylformamide, to give compound
15. Compound 15 is reacted with an appropriate reducing agent, such
as hydrogen gas, in the presence of an appropriate catalyst, such
as Raney nickel, in an appropriate solvent, such as a combination
of water and dimethylformamide, to give compound 16. Compound 16 is
reacted with compound 17 in the presence of an appropriate base,
such as pyridine, in an appropriate solvent, such as
dichloromethane, to give compound 18. Compound 18 is reacted with
compound 19 in the presence of an appropriate base, such as sodium
hydride, in an appropriate solvent, such as dimethylformamide, to
give a compound of formula I.
[0094] Deuterium can be incorporated to different positions
synthetically, according to the synthetic procedures as shown in
Scheme I, by using appropriate deuterated intermediates. For
example, to introduce deuterium at one or more positions of
R.sub.1-R.sub.6, compound 4 with the corresponding deuterium
substitutions can be used. To introduce deuterium at one or more
positions of R.sub.7-R.sub.9, compound 8 with the corresponding
deuterium substitutions can be used. To introduce deuterium at one
or more positions of R.sub.14-R.sub.16, compound 19 with the
corresponding deuterium substitutions can be used. To introduce
deuterium at one or more positions of R.sub.17-R.sub.19, compound
17 with the corresponding deuterium substitutions can be used.
[0095] Deuterium can be incorporated to various positions having an
exchangeable proton, such as the amine N-Hs, via proton-deuterium
equilibrium exchange. For example, to introduce deuterium at one or
more positions of R.sub.10-R.sub.13, these protons may be replaced
with deuterium selectively or non-selectively through a
proton-deuterium exchange method known in the art.
[0096] The invention is further illustrated by the following
examples. All IUPAC names were generated using CambridgeSoft's
ChemDraw 10.0.
[0097] The following compounds can generally be made using the
methods described above. It is expected that these compounds when
made will have activity similar to those described in the examples
above.
##STR00006## ##STR00007## ##STR00008## ##STR00009## ##STR00010##
##STR00011## ##STR00012##
[0098] Changes in the metabolic properties of the compounds
disclosed herein as compared to their non-isotopically enriched
analogs can be shown using the following assays. Compounds listed
above which have not yet been made and/or tested are predicted to
have changed metabolic properties as shown by one or more of these
assays as well.
Biological Activity Assays
In Vitro Liver Microsomal Stability Assay
[0099] Liver microsomal stability assays are conducted at 1 mg per
mL liver microsome protein with an NADPH-generating system in 2%
NaHCO3 (2.2 mM NADPH, 25.6 mM glucose 6-phosphate, 6 units per mL
glucose 6-phosphate dehydrogenase and 3.3 mM MgCl2). Test compounds
are prepared as solutions in 20% acetonitrile-water and added to
the assay mixture (final assay concentration 5 microgram per mL)
and incubated at 37.degree. C. Final concentration of acetonitrile
in the assay should be <1%. Aliquots (50 .mu.L) are taken out at
times 0, 15, 30, 45, and 60 min, and diluted with ice cold
acetonitrile (200 .mu.L) to stop the reactions. Samples are
centrifuged at 12,000 RPM for 10 min to precipitate proteins.
Supernatants are transferred to microcentrifuge tubes and stored
for LC/MS/MS analysis of the degradation half-life of the test
compounds.
In Vitro Metabolism Using Human Cytochrome P.sub.450 Enzymes
[0100] The cytochrome P.sub.450 enzymes are expressed from the
corresponding human cDNA using a baculovirus expression system (BD
Biosciences, San Jose, Calif.). A 0.25 milliliter reaction mixture
containing 0.8 milligrams per milliliter protein, 1.3 millimolar
NADP.sup.+, 3.3 millimolar glucose-6-phosphate, 0.4 U/mL
glucose-6-phosphate dehydrogenase, 3.3 millimolar magnesium
chloride and 0.2 millimolar of a compound of Formula I, the
corresponding non-isotopically enriched compound or standard or
control in 100 millimolar potassium phosphate (pH 7.4) is incubated
at 37.degree. C. for 20 min. After incubation, the reaction is
stopped by the addition of an appropriate solvent (e.g.,
acetonitrile, 20% trichloroacetic acid, 94% acetonitrile/6% glacial
acetic acid, 70% perchloric acid, 94% acetonitrile/6% glacial
acetic acid) and centrifuged (10,000 g) for 3 min. The supernatant
is analyzed by HPLC/MS/MS.
TABLE-US-00001 Cytochrome P.sub.450 Standard CYP1A2 Phenacetin
CYP2A6 Coumarin CYP2B6 [.sup.13C]-(S)-mephenytoin CYP2C8 Paclitaxel
CYP2C9 Diclofenac CYP2C19 [.sup.13C]-(S)-mephenytoin CYP2D6
(+/-)-Bufuralol CYP2E1 Chlorzoxazone CYP3A4 Testosterone CYP4A
[.sup.13C]-Lauric acid
Monoamine Oxidase A Inhibition and Oxidative Turnover
[0101] The procedure is carried out using the methods described by
Weyler, Journal of Biological Chemistry 1985, 260, 13199-13207,
which is hereby incorporated by reference in its entirety.
Monoamine oxidase A activity is measured spectrophotometrically by
monitoring the increase in absorbance at 314 nm on oxidation of
kynuramine with formation of 4-hydroxyquinoline. The measurements
are carried out, at 30.degree. C., in 50 mM NaP.sub.i buffer, pH
7.2, containing 0.2% Triton X-100 (monoamine oxidase assay buffer),
plus 1 mM kynuramine, and the desired amount of enzyme in 1 mL
total volume.
Monooamine Oxidase B Inhibition and Oxidative Turnover
[0102] The procedure is carried out as described in Uebelhack,
Pharmacopsychiatry 1998, 31(5), 187-192, which is hereby
incorporated by reference in its entirety.
L-NAME Treated Renin Transgenic Rats (TGR(mRen2)27)
[0103] The procedure is carried out as described in WO 2007009607,
which is hereby incorporated by reference in its entirety.
5/6 Nephrectomized Rats
[0104] The procedure is carried out as described in WO 2007009607,
which is hereby incorporated by reference in its entirety.
Vasorelaxant Effect In Vitro
[0105] The procedure is carried out as described in U.S. Pat. No.
7,173,037, which is hereby incorporated by reference in its
entirety.
Vasorelaxant Effect In Vitro
[0106] The procedure is carried out as described in U.S. Pat. No.
7,173,037, which is hereby incorporated by reference in its
entirety.
Single-Dose Pharmacokinetics, Pharmacodynamics, Tolerability, and
Safety of Riociguat
[0107] The procedure is carried out as described in Frey et al., J.
Clin. Pharmacol., 2008, 48, 926-34, which is hereby incorporated by
reference in its entirety.
High-Renin Study with Renin-Transgenic L-NAME-Treated Rats
[0108] The procedure is carried out as described in Sharkovska et
al., J. Hypertension, 2010, 28, 1666-1675, which is hereby
incorporated by reference in its entirety.
Low-Renin Study with 5/6 Nephrectomized Wistar Rats
[0109] The procedure is carried out as described in Sharkovska et
al., J. Hypertension, 2010, 28, 1666-1675, which is hereby
incorporated by reference in its entirety.
Effect of Riociguat on Isolated Precontracted Saphenous
Arteries
[0110] The procedure is carried out as described in Sharkovska et
al., J. Hypertension, 2010, 28, 1666-1675, which is hereby
incorporated by reference in its entirety.
Conscious Rabbit Erectile Dysfunction Model
[0111] The procedure is carried out as described in WO 2010081647,
which is hereby incorporated by reference in its entirety.
Intracavernosal Pressure Assay
[0112] The procedure is carried out as described in WO 2010081647,
which is hereby incorporated by reference in its entirety.
Bilateral Cavernous Nerve Crush Model
[0113] The procedure is carried out as described in WO 2010081647,
which is hereby incorporated by reference in its entirety.
[0114] From the foregoing description, one skilled in the art can
easily ascertain the essential characteristics of this invention,
and without departing from the spirit and scope thereof, can make
various changes and modifications of the invention to adapt it to
various usages and conditions.
* * * * *